ZCM
SCLN

Zebra Capital Management’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Zebra Capital Management’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-55,618
Closed -$601K – 304
2016
Q4 		$601K Sell
55,618
-7,285
-12% -$72.8K 0.18% 210
2016
Q3 		$645K Buy
62,903
+9,726
+18% +$106K 0.2% 215
2016
Q2 		$694K Buy
+53,177
New +$697K 0.24% 196
2013
Q3 		– Sell
-13,139
Closed -$65K – 248
2013
Q2 		$65K Buy
+13,139
New +$62.5K 0.05% 228

Other funds holding SCLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Zebra Capital Management's SCLN Position: Q1 2017 in Review

Zebra Capital Management sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q1 2017, closing a stake of 55,618 shares — an estimated $601K sold.

Zebra Capital Management first reported a position in SCLN in Q2 2013 and held it in 4 quarters. The position peaked at $694K in Q2 2016. 136 funds tracked by Wall St. Rank hold SCLN as of Q1 2017.

  • Zebra Capital Management reported no remaining Sciclone Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
  • Zebra Capital Management sold 55,618 Sciclone Pharmaceuticals Inc shares in Q1 2017, an estimated $601K.
  • Zebra Capital Management first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 4 quarters.
  • Zebra Capital Management's Sciclone Pharmaceuticals Inc position peaked at $694K in Q2 2016.
  • 136 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q1 2017.

Based on Zebra Capital Management's 13F filing for Q1 2017, filed 12 May 2017.